PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
PLGA based cancer immunotherapy incorporating antigen and TLR ligands has resulted in enhancement of the anti-tumour response. Here, the authors explore the use of a defined double stranded RNA adjuvant, Riboxxim, and test its incorporation with PLGA immunotherapy in the context of in vivo tumour mo...
Guardado en:
Autores principales: | Julia Koerner, Dennis Horvath, Valerie L. Herrmann, Anna MacKerracher, Bruno Gander, Hideo Yagita, Jacques Rohayem, Marcus Groettrup |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/49f713706d4f4e6c84d91492aa8a5fb5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Xiaopin Duan, et al.
Publicado: (2019) -
Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer
por: Dobrin Draganov, et al.
Publicado: (2021) -
Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy
por: North WG, et al.
Publicado: (2019) -
A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: A. Farias, et al.
Publicado: (2021) -
Games in Rigged Economies
por: Luís F. Seoane
Publicado: (2021)